US companies are separating their top responsibilities at a faster rate than ever before, with shareholder activists often fueling changes
In March, shareholder activists once again filed a proxy proposal asking Pfizer to split the roles of CEO and chairman of the board. Charles Raeburn, Pfizer’s senior corporate counsel, says a similar proposal garnered 41 percent of the shareholder vote last year, and this spring ‘it’s conceivable that it will attract an even higher vote.’ The notion of having a chairman who does not also fill the role of chief executive is steadily gaining traction in the US. High-profile
You need to register to access 3 free deep dive articles per month. To continue reading please register or login below..
- Unlimited deep dives
- Data-driven research around key topics
- Buy-side insights
- Benchmarking reports
From
$1495
